Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: Ferguson C, Inglis SC, Newton PJ, et al. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs 2017: [Epub ahead of print: 8 Feb 2017].
Implications for practice and research
Healthcare professionals need to be aware that age and falls risk are not in themselves barriers to anticoagulation therapy. Anticoagulation therapy should not be withheld based on these factors alone.
Future research should focus on establishing enablers to anticoagulation therapy with the aim of improving compliance.
Atrial fibrillation (AF) currently affects approximately 2% of the population of the Western countries.1 The prevalence of AF rises with concomitant cardiovascular disease, and up to one-third of people with heart failure will also suffer from AF.2 These figures are set to rise further with the continuing ageing population. It is estimated that the number of new AF cases in Europe will rise …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.